← Back to Calendar

Relay Therapeutics Q1 2026 Earnings

Relay Therapeutics · $RLAY
Standard Review Earnings
Catalyst Date
May 7, 2026
Time Remaining
24 days
Review Type
Standard (10 mo)

Live Company Data NGM

Updated just now · Data: FMP
Current Price
$14.94 +572.97%
+$12.72 today
Day: $14.51 – $15.42
Market Cap
N/A
Shares out: 178.73M
Float: 93.67M
52-Week Range
$2.30
$15.42
Current price is at 96% of 52-week range
Avg Volume
2.77M
Beta
1.58
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $RLAY catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q1 2026 earnings + zovegalisib SERENA-PI3K data update

Key Notes

Q1 2026 earnings expected ~May 2026. Expected to include Phase 2 data update from SERENA-PI3K trial — key readout before or at ASCO 2026 (May 29). Update on breast cancer triplet data and frontline Phase 3 timeline.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar